BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TB006 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TB006\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06773962-1727@assetmemo.bio
DTSTAMP:20261121T004532Z
DTSTART;VALUE=DATE:20261128
DTEND;VALUE=DATE:20261129
SUMMARY:TB006: Phase 2 readout est. (NCT06773962)
DESCRIPTION:TB006\, phase 2\, Parkinson's Disease.\nStudy: A Phase 2a Multi
 center Clinical Trial of TB006 in Participants With Parkinson's Disease\nE
 stimated primary completion: 28 November 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tb006#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06773962
URL:https://assetmemo.bio/drug/tb006#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06500637-1727@assetmemo.bio
DTSTAMP:20261121T004532Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:TB006: Phase 2 readout est. (NCT06500637)
DESCRIPTION:TB006\, phase 2.\nStudy: TB006 for Autism Spectrum Disorder\nEs
 timated primary completion: 31 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/tb006#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06500637
URL:https://assetmemo.bio/drug/tb006#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
